Cynata Therapeutics Limited (CYP) Price & Analysis

Compare

9 Followers

CYP Stock Chart & Stats

AU$0.29

-AU$0.01(-4.17%)

At close: Jan 09 4:00 PM EST

AU$0.29

-AU$0.01(-4.17%)

Day’s Range― - ―

52-Week RangeAU$0.14 - AU$0.44

Previous CloseN/A

Volume63.41K

Average Volume (3M)233.82K

Market Cap

AU$87.86M

Enterprise ValueAU$82.81M

Total Cash (Recent Filing)AU$5.05M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.42

Next Earnings

Feb 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding237,454,380

10 Day Avg. Volume170,513

30 Day Avg. Volume233,823

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)5.14

Price to Sales (P/S)16.31

P/FCF Ratio-3.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero debt materially reduces financial risk and preserves strategic optionality for a clinical-stage biotech. Over 2–6 months this improves the company's ability to fund development via equity or partnerships, lowers bankruptcy risk, and makes it a more attractive collaborator for licensors.

High Gross MarginsNear-100% gross margins indicate attractive unit economics for cell therapy manufacturing and licensing. Once development and regulatory hurdles are cleared, high margins can support scalable royalties or product sales, enabling durable profitability if fixed R&D and SG&A are controlled.

Proprietary Allogeneic PlatformCymerus's iPSC‑derived allogeneic MSC approach is structurally scalable relative to autologous therapies. A platform that can address multiple immune/inflammatory indications supports licensing opportunities, recurring royalty streams and strategic partnerships, a durable commercial pathway.

Bears Say

Sustained Cash BurnPersistent negative operating and free cash flow forces reliance on external funding. Over months this elevates dilution risk, can constrain trial progress, and increases execution risk if capital markets or partner interest weaken, threatening program timelines.

Large Operating LossesMeaningful operating losses and negative net margins reflect that current revenues are insufficient to cover R&D and SG&A. Structural improvement requires either successful commercialization or significant partnership deals; absent those, losses will continue to erode equity over time.

No Commercial Revenue / Partnership DependenceBusiness economics are binary: value depends on deals or regulatory approval. Dependence on future partnerships or successful commercialization creates concentrated execution and regulatory risk, making medium-term cashflows uncertain and outcomes highly dependent on third parties.

Cynata Therapeutics Limited News

Cynata to Host Investor Webinar and Expand Online Engagement With Shareholders

Cynata Therapeutics Limited ( ($AU:CYP) ) has provided an update. Cynata Therapeutics has scheduled an investor webinar for...

13d ago

Cynata Nears Key Data Readouts as Pivotal Cell Therapy Trials Advance

Cynata Therapeutics Limited ( ($AU:CYP) ) just unveiled an update. Cynata Therapeutics reported strong clinical and operational progress...

19d ago

Cynata Raises $1.2m via At-The-Market Facility to Support Cell Therapy Pipeline

An announcement from Cynata Therapeutics Limited ( ($AU:CYP) ) is now available. Cynata Therapeutics has raised approximately $1.2...

24d ago

Cynata Completes Enrollment in Phase 2 aGvHD Trial

The latest announcement is out from Cynata Therapeutics Limited ( ($AU:CYP) ). Cynata Therapeutics has completed patient enrollment...

2M ago

Cynata’s CYP-001 Therapy Shows Promise in Kidney Transplant Trial

Cynata Therapeutics Limited ( ($AU:CYP) ) has shared an announcement. Cynata Therapeutics announced a positive review by an...

2M ago

Cynata Therapeutics Updates Director’s Securities Holdings

Cynata Therapeutics Limited ( ($AU:CYP) ) just unveiled an announcement. Cynata Therapeutics Limited announced a change in the...

3M ago

Cynata Therapeutics Announces Change in Director’s Interest

Cynata Therapeutics Limited ( ($AU:CYP) ) has shared an announcement. Cynata Therapeutics Limited announced a change in the...

3M ago

Cynata Therapeutics Announces Change in Director’s Securities Interests

Cynata Therapeutics Limited ( ($AU:CYP) ) just unveiled an announcement. Cynata Therapeutics Limited announced a change in the...

3M ago

Cynata Completes Final Patient Visit in Phase 3 Osteoarthritis Trial

Cynata Therapeutics Limited ( ($AU:CYP) ) has issued an announcement. Cynata Therapeutics Limited announced the completion of the...

3M ago

Cynata Therapeutics Unveils Updated Investor Presentation

Cynata Therapeutics Limited ( ($AU:CYP) ) has shared an update. Cynata Therapeutics Limited has released an updated investor...

3M ago

CYP FAQ

What was Cynata Therapeutics Limited’s price range in the past 12 months?

Cynata Therapeutics Limited lowest share price was AU$0.14 and its highest was AU$0.43 in the past 12 months.

What is Cynata Therapeutics Limited’s market cap?

Cynata Therapeutics Limited’s market cap is AU$87.86M.

When is Cynata Therapeutics Limited’s upcoming earnings report date?

Cynata Therapeutics Limited’s upcoming earnings report date is Feb 19, 2026 which is in 3 days.

How were Cynata Therapeutics Limited’s earnings last quarter?

Cynata Therapeutics Limited released its earnings results on Aug 28, 2025. The company reported -AU$0.025 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.025.

Is Cynata Therapeutics Limited overvalued?

According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cynata Therapeutics Limited pay dividends?

Cynata Therapeutics Limited does not currently pay dividends.

What is Cynata Therapeutics Limited’s EPS estimate?

Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cynata Therapeutics Limited have?

Cynata Therapeutics Limited has 237,454,380 shares outstanding.

What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?

Cynata Therapeutics Limited reported an EPS of -AU$0.025 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.977%.

Which hedge fund is a major shareholder of Cynata Therapeutics Limited?

Currently, no hedge funds are holding shares in AU:CYP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cynata Therapeutics Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-138.54%

Trailing 12-Months

Asset Growth

-15.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cynata Therapeutics Limited

Cynata Therapeutics Limited (CYP) is an Australian biotechnology company focused on the development and commercialization of innovative stem cell therapies. The company specializes in Cymerus™, a proprietary technology for manufacturing mesenchymal stem cells (MSCs) at scale. This platform enables the production of therapeutic stem cells without the limitation of donor availability, supporting the treatment of various diseases and medical conditions. Cynata's core products target applications in regenerative medicine, encompassing indications such as cardiovascular disease, respiratory ailments, and graft-versus-host disease (GvHD).